Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | POLD1 |
| Variant | inact mut |
| Impact List | unknown |
| Protein Effect | loss of function |
| Gene Variant Descriptions | POLD1 inact mut indicates that this variant results in a loss of function of the Pold1 protein. However, the specific amino acid change has not been identified. |
| Associated Drug Resistance | |
| Category Variants Paths |
POLD1 mutant POLD1 inact mut |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04500548 | Phase I | Nivolumab Ipilimumab + Nivolumab | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study | Withdrawn | USA | CAN | 0 |
| NCT07227636 | Phase II | Balstilimab + Botensilimab | A Study of Botensilimab and Balstilimab for Colorectal Cancer | Recruiting | USA | 0 |
| NCT05071209 | Phase Ib/II | Elimusertib | Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors | Active, not recruiting | USA | CAN | 0 |